LivaNova to Wind Down Advanced Circulatory Support Business Unit
LivaNova PLC announced the strategic wind down of its Advanced Circulatory Support (ACS) Business Unit to focus on its core Cardiopulmonary and Neuromodulation units, with a complete transition expected by end of 2024. The company will integrate select ACS cannulae products into its Cardiopulmonary unit, while anticipating a positive impact on its 2024 operating income, despite expected restructuring charges.